Navigation Links
AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
Date:11/3/2008

eated with various chemotherapies.

The study showed that AEZS-108 was well tolerated by patients with gynaecological tumors. Furthermore, AEZS-108 is the first drug in a clinical study that targets the cytotoxic activity of doxorubicin specifically to LHRH-receptor expressing tumors. Finally, signs of anti-tumor activity were observed in 7 out of 13 patients treated with 160 or 267 mg/m2 of AEZS-108, including three patients with complete or partial response.

About AEZS-108

AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors, results in its accumulation in the malignant tissue. This binding is followed by internalization and retention of the cytotoxic drug, doxorubicin, in the cells. Therefore, since they target specific cells, cytotoxic conjugates are postulated to be less toxic, have less side-effects and are more effective in vivo than the respective non-conjugated/non-linked cytotoxic agents in inhibiting tumor growth.

About endometrial and Ovarian Cancer

Cancer of the endometrium is the most common gynaecologic malignancy and accounts for 6% of all cancers in women. The majority of the cases occur in postmenopausal women, with the largest number of women developing their cancers during the sixth decade. Approximately 38,000 new cases and 9,000 deaths from this disease are estimated annually in Europe (Source: Annals of Oncology 15:1149-1150, 2004).

Ovarian cancer is one of the most common gynaecologic malignancies and the fifth most frequent cause of cancer death in women, with most of the cases occurring in women between 50 and 75 years of age. Overall, ovari
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 30, 2014 “PharmaSphere: Emerging Biotech ... Venture Capital Funding” report provides in-depth analysis of ... equity and venture capital segments of the financial ... to have significant impact on the future of ... Furthermore, the report identifies regions of the world ...
(Date:7/29/2014)... The advanced optical methods and applications for imaging ... revolution in the neurosciences were the inspiration behind ... SPIE, the international society for optics and photonics . ... the BRAIN Initiative in the United States, and a ... for and provide examples of the impact that optics ...
(Date:7/29/2014)... JOLLA, Calif. , July 29, 2014 ... diagnostic and therapeutic company focused on extending the healthy, ... hired Franz Och , Ph.D., an expert in ... Data Scientist. Och comes to HLI from Google where ... Google Translate. He will report directly to HLI Co-Founder ...
(Date:7/29/2014)... HOUSTON (July 29, 2014) Tough, ultralight foam ... and shape through a chemical process invented at Rice ... "GO-0.5BN" looks like a nanoscale building, with floors and ... a pair of two-dimensional materials: floors and walls of ... boron nitride platelets. , The researchers say the ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3Tough foam from tiny sheets 2
... markets, the trend in health care employment could be counted on ... bringing yearly growth up over 345,000.The MedZilla.com Employment Report analyzes the ... ... Seattle, WA (Vocus) December 3, 2008 -- The U.S. economy ...
... and HOUSTON, Dec. 2 Transgenomic,Inc. (OTC ... Inc. (OTC,Bulletin Board: PWRM) today announced that ... acquire exclusive rights for Power3 Medical,s Neurodegenerative,Biomarkers, ... Alzheimer,s,and Parkinson,s disease. Transgenomic plans to ...
... postmenopause , , MONTVALE, N.J., ... symptoms is a challenge for women experiencing menopause. OBG ... have recently published a supplement titled Vasomotor symptoms: Managing ... James McGregor, MD, CM and Lee P. Shulman, MD, discuss ...
Cached Biology Technology:The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 2Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 4
(Date:7/30/2014)... roughly 3,000 pieces is still in its infant stage. ... be of major significance. "Amazingly often, we are findingin ... amber that we found in Baltic amber," explained Bonn ... amber comes from the Baltic Sea region, which is ... are, e.g., the coastal regions of Mecklenburg, Poland and ...
(Date:7/30/2014)... scientists unveiled the first high-resolution map of the ... country of Per. The new and improved methodology ... change for future market-based carbon economies. The ... ecological diversity and it provides the critical input ... conservation, land use, and enforcement purposes. The technique ...
(Date:7/29/2014)... Bristol,s Nutrition and Behaviour Unit (NBU) has looked into ... meals. , The research, to be presented at the ... 2014) in Seattle, USA this week [29 July to ... was led by Professor Jeff Brunstrom, and is based ... of a Biotechnology and Biological Sciences Research Council (BBSRC) ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... OCT. 31, 2011 A highly renowned obstetrician, professor ... and diabetic women have a higher risk of becoming ... later in life, received the March of Dimes 2011 ... of maternal-fetal nutrition. , Patrick M. Catalano, ...
... has been mapped. Now, it,s on to proteins, a much ... millions of distinct protein molecules in our bodies. Many of ... A team led by Northwestern University chemical biologist Neil Kelleher ... identify thousands of protein molecules quickly. Many have been skeptical ...
... at Weill Cornell Medical College say they have taken an ... regeneration -- an advance that could effectively treat millions of ... issue of the journal Cell , the research team ... that trigger generation of new lung alveoli, the numerous, tiny, ...
Cached Biology News:March of Dimes honors researcher who linked maternal obesity to a baby's long-term health 2So many proteins, so much promise 2So many proteins, so much promise 3Lung regeneration closer to reality with new discovery by Weill Cornell Medical College researchers 2Lung regeneration closer to reality with new discovery by Weill Cornell Medical College researchers 3Lung regeneration closer to reality with new discovery by Weill Cornell Medical College researchers 4
...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Assay Diluent Trial Pack, 4 x 100 mL...
Biology Products: